RESEARCH TRIANGLE PARK – Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.
The company said it will expand the production capacity at its Hamilton facility, where it produces components used in several of vaccines, including ones to help prevent malaria and its Shingrix shingles treatment.
“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, president, of US Pharmaceuticals at GSK. “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix.”
360,000 children in Africa to receive first malaria vaccine which GSK developed
Over the next few years, the company says its Hamilton site expansion is expected to add a combination of temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers and manufacturing and quality professionals.
It did not provide specific numbers.
The Hamilton facility is one of nine GSK manufacturing sites in the United States, including one in Zebulon.
GSK maintains as well a major presence in RTP.
GSK’s top exec sees ‘good progress’ but drug giant forecasts decline in earnings
